The 18th International Conference on Malignant Lymphoma (18-ICML), hosted by the Fondazione Internazionale per la Ricerca sul Cancro (IOR), was held from June 17–21, 2025, in Lugano, Switzerland. As a…

In the field of hematopoietic stem cell transplantation (HSCT), early identification and precise intervention of graft-versus-host disease (GVHD) remain among the key challenges in clinical management. At the 2025 European…

Recently, a multi-center research team led by Professor Xiaoxia Hu (Ruijin Hospital, Shanghai Jiao Tong University School of Medicine), Professor Yang Cao (Tongji Hospital, Tongji Medical College, Huazhong University of…

A groundbreaking study titled “MRD and NK-Cell Chimerism Predict Transplant Outcomes in Allogeneic Hematopoietic Stem Cell Transplantation Recipients” has been recently published online in the American Journal of Hematology. This…

The 18th International Conference on Malignant Lymphoma (18-ICML), hosted by the Institute of Oncology Research (IOR), was held from June 17–21, 2025, in Lugano, Switzerland. As one of the world's…

The 2025 Annual Conference of the Chinese Society of Clinical Oncology (BOC), held in conjunction with Best of ASCO 2025 China (BOC/BOA), will take place from July 4–5 in the historic city of Nanjing. This prestigious event will gather leading oncology experts from across China and around the world to reflect on major clinical oncology advances in China over the past year and to present key takeaways from the recently concluded American Society of Clinical Oncology (ASCO) Annual Meeting.

The 18th International Conference on Malignant Lymphoma (ICML), hosted by the Institute of Oncology Research (IOR), took place in Lugano, Switzerland, from June 17 to 21, 2025. As one of…

As vibrant blossoms filled the streets of Shanghai and the Huangpu River shimmered beneath the morning sun, the 2025 Hematology Translational and Innovation Conference, held in parallel with the 10th Shanghai Lymphoid Disease Symposium, was convened from June 27 to 29. This prominent academic event brought together leading experts from China and abroad to share research achievements and foster the translation of basic science into clinical advances. With a focus on innovative therapies, professional education, and scientific communication, the conference provided a dynamic platform for collaboration and progress.

As summer bloomed in Shanghai and the tide of the Huangpu River caught the morning light, the 2025 Hematology Translational and Innovation Conference, held in parallel with the 10th Shanghai Lymphoid Disease Symposium, took place from June 27 to 29. This major academic event welcomed prominent experts from China and abroad to share cutting-edge achievements, promote the integration of basic science and clinical application in hematology, and foster broad exchanges around emerging therapies, professional training, and science communication.

From June 20 to 22, the 19th Annual Meeting of the Chinese Medical Doctor Association Hematology Branch and the 2025 China Hematology Conference (CAH 2025) was held in the historic city of Xi’an. As a major academic event in China’s hematology community, the conference maintained its core mission of “serving clinical practice,” with a strong focus on treatment standardization, practical application, and multicenter collaboration, fostering deep integration of academic exchange and clinical implementation. During the event, Oncology Frontier – Hematology Frontier interviewed Professor Jin Lu from Peking University People's Hospital, Executive Chair of CAH 2025, for an in-depth conversation on the highlights of this year’s conference and the development of multiple myeloma (MM) care in China.